{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:24:09Z","timestamp":1792506249407,"version":"4.5.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic nutritional index (PNI) has been associated with survival outcomes in multiple solid tumors, yet its prognostic relevance in prostate cancer patients undergoing androgen deprivation therapy (ADT)-based systemic treatment remains insufficiently characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Infrastructure (CNKI) from database inception to September 11, 2025. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the association between PNI and survival outcomes; pooled odds ratios (ORs) with 95% CIs evaluated links with clinicopathological features. Subgroup analyses explored heterogeneity sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten retrospective studies involving 1, 847 patients were included. Low PNI was significantly associated with worse overall survival (HR = 2.082, 95% CI: 1.756\u20132.469,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Due to heterogeneous definitions of disease progression across studies, progression-related endpoints were analyzed separately by type. Low PNI consistently predicted inferior outcomes across multiple progression-free survival metrics: PFS (HR = 1.606, 95% CI: 1.328\u20131.942), radiographic PFS (rPFS; HR = 2.315, 95% CI: 1.525\u20133.514), and PSA-PFS (HR = 3.176, 95% CI: 2.169\u20134.652) (all\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Subgroup analyses supported result robustness. Additionally, low PNI correlated significantly with Gleason score &amp;gt;7 (OR = 1.404,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018), bone metastasis (OR = 1.433,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.015), LATITUDE high-risk status (OR = 1.898, p = 0.003), and CHAARTED-defined high tumor burden (OR = 1.950,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001), but not with age, visceral metastases, or EAU high-risk classification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the context of ADT-based systemic therapy, low PNI is a significant predictor of poor survival and aggressive disease features, supporting its potential as a readily available biomarker for risk stratification and prognostic assessment in prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251145397.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1794606","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:30:16Z","timestamp":1773120616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Huanli","family":"Huang","sequence":"first","affiliation":[{"name":"First Clinical College, Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwei","family":"Lan","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine, Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Li","sequence":"additional","affiliation":[{"name":"First Clinical College, Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]},{"name":"Department of Radiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0588-8","article-title":"Comparison between prognostic classifications in de novo metastatic hormone sensitive prostate cancer","volume":"13","author":"Iacovelli","year":"2018","journal-title":"Target Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.07.026","article-title":"Prostate-specific antigen flare phenomenon induced by abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Ueda","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.05.025","article-title":"Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer","volume":"38","author":"Kafka","year":"2020","journal-title":"Urol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.814727","article-title":"Prognostic significance of the systemic immune-inflammation index (SII) in patients with small cell lung cancer: A meta-analysis","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12937-023-00863-8","article-title":"Prognostic and clinicopathological impacts of Controlling Nutritional Status (CONUT) score on patients with gynecological cancer: a meta-analysis","volume":"22","author":"Niu","year":"2023","journal-title":"Nutr J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906711","article-title":"Geriatric nutritional risk index and survival of patients with colorectal cancer: A meta-analysis","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21141","article-title":"Prognostic Effect of Albumin-to-Globulin Ratio in Patients with solid tumors: A Systematic Review and Meta-analysis","volume":"8","author":"He","year":"2017","journal-title":"J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S499094","article-title":"The effect of systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) in early gastric cancer","volume":"17","author":"Jing","year":"2024","journal-title":"J Inflammation Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1186\/s12885-025-14823-4","article-title":"Prognostic value of nutritional risk assessment indices in patients with digestive system tumors","volume":"25","author":"Zeng","year":"2025","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30030197","article-title":"Predictive value of inflammatory and nutritional indexes in the pathology of bladder cancer patients treated with radical cystectomy","volume":"30","author":"Prijovic","year":"2023","journal-title":"Curr Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102142","article-title":"Prognostic nutritional index (PNI) as independent predictor of poor survival in prostate cancer: A systematic review and meta-analysis","volume":"22","author":"Tobing","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00689-9","article-title":"Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis","volume":"27","author":"Zheng","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24619","article-title":"Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study","volume":"83","author":"Yamada","year":"2023","journal-title":"Prostate"},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175434","article-title":"The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma","volume":"12","author":"Ellez","year":"2023","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2021.12.005","article-title":"Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide","volume":"46","author":"K\u00fc\u00e7\u00fckarda","year":"2022","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12885-020-06879-1","article-title":"Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer","volume":"20","author":"Li","year":"2020","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61061105","article-title":"Prognostic nutritional index and a blood-based prognostic tool in prostate cancer treated with abiraterone, enzalutamide or cabazitaxel","volume":"61","author":"Taban","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23381","article-title":"Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"77","author":"Fan","year":"2017","journal-title":"Prostate"},{"key":"B30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/pros.24876","article-title":"Prognostic nutritional index as a biomarker in metastatic hormone-sensitive prostate cancer: impact on survival and treatment optimization","volume":"85","author":"Hacioglu","year":"2025","journal-title":"Prostate"},{"key":"B31","unstructured":"Wang\n              YQ\n            \n            \n              Wei\n              X\n            \n          \n          Shanghai\n          Shanghai Jiao Tong University\n          Precise diagnosis and prognostic evaluation of prostate cancer\n          \n          2017"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.13898\/j.cnki.issn.1000-2200.2022.07.004","article-title":"Significance of PNI and NLR for predicting initial efficacy and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate and prednisone","volume":"47","author":"Sun","year":"2022","journal-title":"J Bengbu Med Coll"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn421213-20210821-01246","article-title":"Prognostic factors in patients with high-volume disease metastatic hormone-sensitive prostate cancer","volume":"39","author":"Ma","year":"2022","journal-title":"Chin J Exp Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuroe.2021.03.005","article-title":"The prognostic nutritional index as an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide","volume":"45","author":"K\u00fc\u00e7\u00fckarda","year":"2021","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2024.106588","article-title":"PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight","volume":"243","author":"Galey","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1436063","article-title":"Prognostic value of three clinical nutrition scoring system (NRI, PNI, and CONUT) in elderly patients with prostate cancer","volume":"11","author":"Li","year":"2024","journal-title":"Front Nutr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i25.8863","article-title":"Evaluation of the prognostic nutritional index for the prognosis of Chinese patients with high\/extremely high-risk prostate cancer after radical prostatectomy","volume":"10","author":"Yang","year":"2022","journal-title":"World J Clin Cases"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24263","article-title":"The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot-assisted laparoscopic radical prostatectomy","volume":"82","author":"Li","year":"2022","journal-title":"Prostate"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2020.1795694","article-title":"Preoperative nutritional risk index predicts recurrence of oligometastatic prostate cancer in patients undergoing cytoreductive radical prostatectomy","volume":"73","author":"Guo","year":"2021","journal-title":"Nutr Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S151314","article-title":"Prognostic value of selected preoperative inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy","volume":"11","author":"Shu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S458666","article-title":"Correlation of prognostic nutritional index and systemic immune-inflammation index with the recurrence and prognosis in oral squamous cell carcinoma with the stage of III\/IV","volume":"17","author":"Ye","year":"2024","journal-title":"Int J Gen Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(80)90246-9","article-title":"Prognostic nutritional index in gastrointestinal surgery","volume":"139","author":"Buzby","year":"1980","journal-title":"Am J Surg"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400050051011","article-title":"The use of albumin in clinical practice","volume":"151","author":"Erstad","year":"1991","journal-title":"Arch Intern Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12935-020-1094-5","article-title":"Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-192559","article-title":"Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals","volume":"113","author":"Maeda","year":"2009","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065082","article-title":"LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-\u03baB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects","volume":"24","author":"Duprat","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0718-299R","article-title":"Senescent cells: Living or dying is a matter of NK cells","volume":"105","author":"Antonangeli","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.597675","article-title":"Inflammation and skeletal muscle wasting during cachexia","volume":"11","author":"Webster","year":"2020","journal-title":"Front Physiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207746","article-title":"The impact of inflammation and acute phase activation in cancer cachexia","volume":"14","author":"Robinson","year":"2023","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/nu15071631","article-title":"Androgen deprivation therapy for prostate cancer influences body composition increasing risk of sarcopenia","volume":"15","author":"Korczak","year":"2023","journal-title":"Nutrients"},{"key":"B51","article-title":"Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer","volume":"36","author":"Yamasaki","year":"2016","journal-title":"Anticancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines","volume":"7","author":"M\u00e9n\u00e9trier-Caux","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215000","article-title":"Targeting inflammatory signaling in prostate cancer castration resistance","volume":"10","author":"Zhong","year":"2021","journal-title":"J Clin Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382417","article-title":"Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Hou","year":"2024","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0271821","DOI":"10.1371\/journal.pone.0271821","article-title":"Prognostic nutritional index as a prognostic factor for renal cell carcinoma: A systematic review and meta-analysis","volume":"17","author":"Shim","year":"2022","journal-title":"PLoS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/01635581.2022.2104879","article-title":"The prognostic value of prognostic nutritional index in patients with ovarian cancer: A systematic review and meta-analysis","volume":"75","author":"Tan","year":"2023","journal-title":"Nutr Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1159\/000531884","article-title":"Prognostic ability of nutritional indices for outcomes of bladder cancer: A systematic review and meta-analysis","volume":"107","author":"Jiao","year":"2023","journal-title":"Urol Int"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2288705","article-title":"Prognostic and clinicopathological effect of the prognostic nutritional index (PNI) in patients with cervical cancer: a meta-analysis","volume":"55","author":"Niu","year":"2023","journal-title":"Ann Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1794606\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:30:20Z","timestamp":1773120620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1794606\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":62,"alternative-id":["10.3389\/fonc.2026.1794606"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1794606","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1794606"}}